For laboratory and research use only. Not for human consumption.
Skin & Hair

Nonapeptide-1

Also known as: Melanostatine 5, Melanostatine-5, Nonapeptide-1 acetate

Research
Share:
Last reviewed

Key Facts: Nonapeptide-1

Category
Skin & Hair
FDA Status
Not FDA Approved
Clinical Status
Cosmetic use - Available in brightening skincare. Cosmetic ingredient, not an FDA-approved drug. No independent peer-reviewed human trials of the peptide alone.
Banned in Sport (WADA)
Not named on the WADA Prohibited List (2026). As a topical cosmetic ingredient it is not a known anti-doping issue, but injecting it as an unapproved drug would fall under WADA's S0 catch-all.
Administration
Topical (serums, creams)
Typical Dose
Low percentage in a brightening serum
Frequency
Once or twice daily
Duration
Brightening claims are usually judged over 8 to 12 weeks; ongoing use
Also Known As
Melanostatine 5, Melanostatine-5, Nonapeptide-1 acetate

How does Nonapeptide-1 work?

When skin is hit by UV, it releases alpha-MSH, which binds the MC1R receptor on melanocytes and switches on tyrosinase, the enzyme that makes melanin. Nonapeptide-1 is designed to sit in that receptor without switching it on, a competitive antagonist, so less of the tanning and pigment signal gets through. In cell studies it binds MC1R with high affinity and blocks alpha-MSH-driven melanosome dispersion at nanomolar levels, and it lowered tyrosinase and related pigment genes in human melanocytes. It is essentially the opposite of melanotan I and afamelanotide, which activate the same receptor to darken skin. The big unknown, as with most cosmetic peptides, is how much reaches melanocytes through intact skin.

What does the research show?

The evidence is thin and mostly commercial. Receptor binding and anti-pigment effects come from cell work and supplier data sheets. In a 2022 paper in Postepy Dermatologii i Alergologii (Chen and colleagues), nonapeptide-1 was used as a reference MC1R blocker in UVA-exposed human melanocytes and keratinocytes, where it reduced pigment pathway activity, but the study's focus was tea polyphenols, not the peptide. Ingredient databases describe the human data as small and manufacturer-generated. You will see claims online of a 12-week, 40-person trial where a cream with this peptide matched 4 percent hydroquinone for melasma, but we could not find a published, citable version, and even then it was a multi-ingredient cream. Fair summary: a well-designed molecule with a clear mechanism in cells, and very little real-world proof. Sunscreen still does more for dark spots than any single brightening peptide.

Trial Progress:Phase I
Pre
I
II
III
IV
FDA

What doses have been studied?

Limited Research·Cell and receptor studies plus unpublished manufacturer data; no independent human trials

Typical Dosingⓘ

Community experience

Common Dose

Low percentage in a brightening serum

Range

Not standardized

Frequency

Once or twice daily

Results for any brightening ingredient depend heavily on daily sun protection. Hyperpigmentation that is new, changing, or uneven in color should be looked at by a dermatologist before you try to fade it.

Research Dosingⓘ

Scientific studies

Cosmetic formulation levels, not a dose recommendation

Duration

Brightening claims are usually judged over 8 to 12 weeks; ongoing use

Administration

Topical (serums, creams)

When and how is Nonapeptide-1 taken?

Best Time to Take

Morning (under sunscreen) and/or evening

Once or twice daily on clean skin

Food Recommendation

With or without food

Why This Timing?

No timing data exist. Morning use under sunscreen makes sense since UV is the main trigger for the pigment signal it blocks.

What are the side effects of Nonapeptide-1?

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • ●Generally well tolerated
  • ●Mild irritation (uncommon)
  • ●No systemic effects expected from topical use
  • ●Brightening products do nothing if you skip sunscreen

References

Research This Peptide Further

Frequently Asked Questions

What does Nonapeptide-1 do?

Nonapeptide-1, sold as Melanostatine 5, is a nine-amino-acid synthetic peptide built to block alpha-MSH, the hormone that tells pigment cells to make melanin. It goes into brightening and dark-spot products as a gentler alternative to harsh lighteners. It is a cosmetic ingredient, not an FDA-approved drug, and there is no independent peer-reviewed clinical trial of it on its own.

How does Nonapeptide-1 work?

When skin is hit by UV, it releases alpha-MSH, which binds the MC1R receptor on melanocytes and switches on tyrosinase, the enzyme that makes melanin. Nonapeptide-1 is designed to sit in that receptor without switching it on, a competitive antagonist, so less of the tanning and pigment signal gets through. In cell studies it binds MC1R with high affinity and blocks alpha-MSH-driven melanosome dispersion at nanomolar levels, and it lowered tyrosinase and related pigment genes in human melanocytes. It is essentially the opposite of melanotan I and afamelanotide, which activate the same receptor to darken skin. The big unknown, as with most cosmetic peptides, is how much reaches melanocytes through intact skin.

Is Nonapeptide-1 FDA approved?

No, Nonapeptide-1 is not currently FDA approved. Current status: Cosmetic use - Available in brightening skincare. Cosmetic ingredient, not an FDA-approved drug. No independent peer-reviewed human trials of the peptide alone.

Is Nonapeptide-1 banned in sport?

Not named on the WADA Prohibited List (2026). As a topical cosmetic ingredient it is not a known anti-doping issue, but injecting it as an unapproved drug would fall under WADA's S0 catch-all.

What are the side effects of Nonapeptide-1?

Reported side effects include: Generally well tolerated, Mild irritation (uncommon), No systemic effects expected from topical use, Brightening products do nothing if you skip sunscreen. Individual responses vary based on dosage, duration, and personal health factors.

What is the typical dose of Nonapeptide-1?

Community-reported common dose: Low percentage in a brightening serum (Once or twice daily). Range: Not standardized. Administration: Topical (serums, creams). Community-reported doses. Not medical advice. Consult healthcare provider.

Related Peptides

Peptides commonly compared with Nonapeptide-1 or used in similar applications.

GHK-Cu

Clinical Trials

GHK-Cu is the copper(II) complex of GHK, a naturally occurring human tripeptide (glycyl-L-histidyl-L-lysine) found in blood plasma, saliva and urine, whose levels decline with age. It is researched and widely used in cosmetic skincare for skin regeneration, wound healing, collagen support and anti-aging. It is not an FDA-approved drug; it appears in over-the-counter cosmetics and as a research or compounded peptide, with most human evidence coming from small topical-skincare studies.

Skin & Hair

Snap-8

Research

SNAP-8 (Acetyl Octapeptide-3) is a synthetic eight-amino-acid topical cosmetic peptide, an extended cousin of Argireline that adds two residues to the same SNAP-25 mimic sequence. It is marketed as a needle-free way to soften expression lines, especially on the forehead and around the eyes. It is a cosmetic ingredient, not an approved drug, and the human evidence behind it is thin and mostly comes from the manufacturer.

Skin & Hair

Argireline

Research

Argireline is the trade name for acetyl hexapeptide-8 (sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2, also called acetyl hexapeptide-3), a synthetic peptide sold in anti-aging creams as a topical, needle-free alternative to Botox. It is designed to relax the muscle contractions behind expression lines. It is a cosmetic ingredient, not an FDA-approved drug, and the human efficacy data are genuinely mixed rather than settled.

Skin & Hair

Matrixyl

Research

Matrixyl is the trade name (Sederma) for palmitoyl pentapeptide-4, also written Pal-KTTKS, a collagen-fragment peptide attached to a fatty acid so it can cross skin. Unlike Botox-mimic peptides, it does not touch muscle: it signals skin cells to rebuild collagen, so it is aimed at fine lines, firmness and skin texture rather than expression wrinkles. It is a cosmetic ingredient with one of the better-documented topical studies in the peptide space, though far short of drug-grade proof.

Skin & Hair

Matrixyl 3000

Research

Matrixyl 3000 is Sederma's follow-up to the original Matrixyl, a fixed pair of two fatty-acid-tagged peptides: palmitoyl tripeptide-1 (Pal-GHK) and palmitoyl tetrapeptide-7 (Pal-GQPR). The idea is a one-two punch: one peptide tells skin to rebuild collagen, the other calms the low-grade inflammation that wears collagen down. It is a cosmetic ingredient aimed at firmness, fine lines and aging skin, with supportive but mostly company-generated evidence.

Skin & Hair

Copper Peptide AHK-Cu

Research

AHK-Cu is a synthetic copper-bound tripeptide, alanine-histidine-lysine complexed with a copper ion, engineered mainly for hair and scalp products. It is the lesser-known sibling of the naturally occurring GHK-Cu copper peptide, designed in the lab specifically to push hair follicles to keep growing. It is a cosmetic and research ingredient, not an approved hair-loss drug, and its evidence is essentially limited to one notable lab study.

Skin & Hair

Want updates on Nonapeptide-1 research?

Get an email when we add new research here, when it is back in stock, or when the price drops.